The PECATI trial, presented at ESMO 2024, brings promising news for patients with advanced B3 thymoma and thymic carcinoma, rare types of cancer originating in the thymus gland. This study evaluated the combination of two drugs, lenvatinib and pembrolizumab, in patients who had already undergone other treatments and did not have autoimmune disorders. In the…